#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ovarian cancer Myasthenia gravis Multifocal motor neuropathy Synovial sarcoma recurrent Pleomorphic leiomyosarcoma Rhabdoid tumour Ovarian epithelial cancer Small intestine leiomyosarcoma Acute myeloid leukaemia (in remission) Waldenstrom's macroglobulinaemia recurrent Encephalopathy neonatal Cholangiocarcinoma Acute respiratory distress syndrome Gestational trophoblastic tumour Pustular psoriasis More trials…

    Learn about Rare Diseases

    Prader-Willi syndrome – Diagnostics Cystic fibrosis lung – Trials in Disease Angiosarcoma metastatic – Trials in Disease IgA nephropathy – Basic Information Mantle cell lymphoma stage IV – Treatment Pleural mesothelioma malignant – Trials in Disease Marginal zone lymphoma refractory Carcinoid syndrome – Trials in Disease Atypical teratoid/rhabdoid tumour of CNS – Basic Information Myelodysplastic syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Terlipressin Osilodrostat Allopurinol Sodium Oms906 Hct116-A Protrans Octreotide O15-Water Giredestrant Ale.c04 Sonidegib Caspofungin Acetate Ucp4 Ammonium Chloride Bp SODIUM SULFIDE NONAHYDRATE Pegfilgrastim Volrustomig Arachis Hypogaea Extract Stro-002 Wt1/Il15/Il15Ra Mrna Dc More therapies…

    Learn about Your Condition

    Vestibular disorder Streptococcal infection Post procedural hypotension Pancreatic neoplasm Naevoid melanoma Lymphoedema EGFR gene mutation Pulmonary embolism Arginase deficiency Endocarditis bacterial Haemorrhagic stroke Metastases to biliary tract Ovarian granulosa cell tumour Gingival bleeding Rubella More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hepatocellular carcinoma

  • Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    France Ireland Italy Romania Spain

  • A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

    Recruiting

    3 1 1
    Investigated Drugs:
    • Belzutifan
    • Lenvatinib
    Belgium Czechia Denmark Finland France Germany +4

  • A study of pumitamig and ipilimumab in patients with advanced or unresectable liver cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    • Ipilimumab
    France Germany Italy Poland Spain

  • A study to investigate the safety and effects of ceralasertib, tremelimumab, and durvalumab in adults with various solid tumors

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Hyaluronidase (Human Recombinant)
    • Durvalumab
    • Infliximab
    Poland

  • A study testing visugromab, nivolumab, and lenvatinib for patients with advanced liver cancer that cannot be removed by surgery after previous treatment failed

    Recruiting

    2 1 1
    Investigated Drugs:
    • VISUGROMAB
    • Lenvatinib
    • Nivolumab
    France Germany Italy Spain

  • Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors

    Recruiting

    3 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Metastatic malignant melanoma
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Vusolimogene Oderparepvec
    • RP2
    • RP3
    France Germany Greece Poland Spain
1 2 3 … 15
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!